Slate Bio is a privately held, pre-clinical stage biotechnology company spun out of the University of Virginia School of Medicine. The company is developing paradigm‑shifting IL-2 compounds; its lead candidate, IL233, is a bifunctional IL-2 fusion cytokine that augments regulatory T cells and tissue‑resident Tregs. IL233 combines IL-2 and IL-33 to provide synergy, greater tissue selectivity, improved pharmacodynamics and durability, and has induced persistent remission in animal models of autoimmune and inflammatory diseases. Slate positions IL233 to address limitations of native IL-2 and approaches like Fc‑fusions and PEGylated low‑dose IL-2, which suffer from short half-life, narrow therapeutic windows and limited durability. The company recently closed a $1.75 million seed financing to advance its pre-clinical program. Management and investors have highlighted the team’s experience and the opportunity to develop therapies for patients with unmet medical needs.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2021